AVALO THERAPEUTICS, INC. Retained Earnings
AVALO THERAPEUTICS, INC. (AVTX) had Retained Earnings of -$504.51 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$504.51M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$468.15M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$448.52M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$434.80M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$504.51M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$468.15M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$448.52M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$434.80M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$404.18M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$383.41M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$370.26M 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$334.92M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$357.96M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$456.42M 10-Q/A · filed 2024-07-11 | |
| 2023-12-31 | -$335.13M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$326.97M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$321.74M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$313.78M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$303.82M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$294.01M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | -$297.20M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$284.22M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$262.17M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$242.97M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$225.57M 10-Q · filed 2021-08-02 | |
| 2021-03-31 | -$208.47M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$177.79M 10-K · filed 2022-03-02 | -$177.79M 10-K · filed 2021-03-08 |
| 2020-09-30 | -$162.15M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$148.69M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$135.41M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$114.29M 10-K · filed 2021-03-08 | |
| 2019-09-30 | -$115.91M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$111.90M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$105.67M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$98.22M 10-K · filed 2020-03-11 | |
| 2018-09-30 | -$92.66M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$68.06M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$62.05M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | -$58.17M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$55.07M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$73.79M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | -$72.00M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$70.04M 10-K · filed 2018-04-02 | |
| 2016-09-30 | -$68.40M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | -$62.23M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | -$58.70M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | -$53.56M 10-K · filed 2017-03-14 | |
| 2015-09-30 | -$49.91M 10-Q · filed 2015-11-13 | |
| 2014-12-31 | -$43.07M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |